Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014 BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction wi...
Intrexon to Acquire Trans Ova Genetics
Trans Ova Platform Combined with Intrexon's Technologies to Advance Cattle Genetics SIOUX CENTER, Iowa and GERMANTOWN, Md., July 1, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies.  Trans Ova's dedication and strong commitment to its customers, which has sustained its outstanding reputation within its industry, will continue unabated.  Trans Ova will become a wholly owned subsidiary of Intrexon under the leadership of David Faber, D.V.M., President, and his current management team.  Over...
Intrexon's Industrial Products Division Achieves Bioconversion of Methane to Farnesene
Second Product of Intrexon's Proprietary Bioconversion Platform Following Isobutanol Intrexon's Gas-to-Liquids Approach Significantly More Cost-Efficient Versus Conventional Methods SAN CARLOS, Calif., June 30, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its Industrial Products Division has achieved the bioconversion of methane to farnesene in the lab with its proprietary platform. Farnesene is a key building block chemical for diesel fuel, and also for other lubricants and specialty products, including cosmetics, rubber, and plastics. This is the second product, following isobutanol, which Intrexon has upgraded from natural ga...